DeVita VT, Rosenberg SA. Two hundred years of cancer research. N Engl J Med. 2012;366:2207–14.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Criscitiello C, Morganti S, Curigliano G. Antibody-drug conjugates in solid tumors: a look into novel targets. J Hematol Oncol. 2021;14.

Drago JZ, Modi S, Chandarlapaty S. Unlocking the potential of antibody-drug conjugates for cancer therapy. Nat Rev Clin Oncol. 2021;18:327–44.

Article  PubMed  PubMed Central  Google Scholar 

Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367:1783–91.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pomeroy AE, Schmidt EV, Sorger PK, Palmer AC. Drug independence and the curability of cancer by combination chemotherapy. Trends Cancer. 2022;8:915–29.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yardley DA. Drug resistance and the role of combination chemotherapy in improving patient outcomes. Int J Breast Cancer. 2013;2013:1–15.

Article  Google Scholar 

Abrahams C, Krimm S, Li X, Zhou S, Hanson J, Masikat MR, et al. Abstract NT-090: Preclinical activity and safety of STRO-002, a novel ADC targeting folate receptor alpha for ovarian and endometrial cancer. Clinical Cancer Res. 2019;25:NT-090. https://doi.org/10.1158/1557-3265.OVCASYMP18-NT-090

Quanz M, Hagemann UB, Zitzmann-Kolbe S, Stelte-Ludwig B, Golfier S, Elbi C, et al. Anetumab ravtansine inhibits tumor growth and shows additive effect in combination with targeted agents and chemotherapy in mesothelin-expressing human ovarian cancer models. Oncotarget. 2018;9:34103–21.

Article  PubMed  PubMed Central  Google Scholar 

Ponte JF, Ab O, Lanieri L, Lee J, Coccia J, Bartle LM, et al. Mirvetuximab Soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, potentiates the activity of standard of care therapeutics in ovarian cancer models. Neoplasia. 2016;18:775–84.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Moore KN, O’Malley DM, Vergote I, Martin LP, Gonzalez-Martin A, Malek K, et al. Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer. Gynecol Oncol. 2018;151:46–52.

Article  CAS  PubMed  Google Scholar 

O’Malley DM, Matulonis UA, Birrer MJ, Castro CM, Gilbert L, Vergote I, et al. Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer. Gynecol Oncol. 2020;157:379–85.

Article  PubMed  Google Scholar 

Bulat I, Moore KN, Haceatrean A, Chung JW, Rajagopalan P, Xia C, et al. Abstract 5571: Phase Ib study of anti-mesothelin antibody drug conjugate anetumab ravtansine in combination with pegylated liposomal doxorubicin in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer. 2018;36:5571–5571.

Levy B, Paz-Ares L, Rixe O, Su W-C, Yang T-Y, Tolcher A, et al. MA13.07 TROPION-Lung02: initial results for datopotamab deruxtecan plus pembrolizumab and platinum chemotherapy in advanced NSCLC. J Thoracic Oncol 2022;17:S91.

Janjigian YY, Oh D-Y, Rha SY, Lee KW, Steeghs N, Chao Y, et al. Abstract 295: Dose-escalation and dose-expansion study of trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2+ gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03. 2022;40:295–295.

Kan S, Koido S, Okamoto M, Hayashi K, Ito M, Kamata Y, et al. Up-regulation of HER2 by gemcitabine enhances the antitumor effect of combined gemcitabine and trastuzumab emtansine treatment on pancreatic ductal adenocarcinoma cells. BMC Cancer. 2015;15.

Tseng CJ, Wang YJ, Liang YC, Jeng JH, Lee W Sen, Lin JK, et al. Microtubule damaging agents induce apoptosis in HL 60 cells and G2/M cell cycle arrest in HT 29 cells. Toxicology. 2002;175:123–42.

Wahl AF, Donaldson KL, Mixan BJ, Trail PA, Siegall CB. Selective tumor sensitization to taxanes with the mAb-drug conjugate cBR96-doxorubicin. Int J Cancer. 2001;93:590–600.

Article  CAS  PubMed  Google Scholar 

Martin M, Fumoleau P, Dewar JA, Albanell J, Limentani SA, Campone M, et al. Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study. Ann Oncol. 2016;27:1249–56.

Article  CAS  PubMed  Google Scholar 

Cortés J, Diéras V, Lorenzen S, Montemurro F, Riera-Knorrenschild J, Thuss-Patience P, et al. Efficacy and safety of trastuzumab emtansine plus capecitabine vs trastuzumab emtansine alone in patients with previously treated ERBB2 (HER2)-positive metastatic breast cancer: a phase 1 and randomized phase 2 trial. JAMA Oncol. 2020;6:1203–9.

Article  PubMed  Google Scholar 

Patel TA, Ensor J, Rodriguez AA, Belcheva A, Darcourt JG, Niravath PA, et al. Phase ib study of trastuzumab emtansine (TDM1) in combination with lapatinib and nab-paclitaxel in metastatic HER2-neu overexpressed breast cancer patients: Stela results. J Clin Oncol. 2018;36:1035–1035.

Article  Google Scholar 

Patel TA, Ensor JE, Creamer SL, Boone T, Rodriguez AA, Niravath PA, et al. A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study). Breast Cancer Res. 2019;21.

López-Miranda E, Pérez-García JM, Di Cosimo S, Brain E, Ravnik M, Escrivá-De-romaní S, et al. Trastuzumab emtansine plus non-pegylated liposomal doxorubicin in HER2-positive metastatic breast cancer (thelma): a single-arm, multicenter, phase Ib trial. Cancers (Basel). 2020;12:1–14.

Article  Google Scholar 

Zimmer AS, Steinberg SM, Smart DD, Gilbert MR, Armstrong TS, Burton E, et al. Temozolomide in secondary prevention of HER2-positive breast cancer brain metastases. Future Oncol. 2020;16:899–909.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Planchard D, Brahmer JR, Yang JC, Chen Y-M, Lee K-Y, Suksombooncharoen T, et al. Abstract CT572: Phase 1b dose-escalation and dose-expansion study evaluating trastuzumab deruxtecan (T-DXd) in combination with durvalumab and cisplatin, carboplatin, or pemetrexed in advanced or metastatic, HER2-overexpressing, nonsquamous non-small cell lung cancer (NSCLC): DESTINY-Lung03. Cancer Res. 2022;82:CT572–CT572. https://doi.org/10.1158/1538-7445.AM2022-CT572

O’Donnell PH, Milowsky MI, Petrylak DP, Hoimes CJ, Flaig TW, Mar N, et al. Enfortumab vedotin with or without pembrolizumab in cisplatin-ineligible patients with previously untreated locally advanced or metastatic urothelial cancer. J Clin Oncol. 2023.

Le X, Carneiro BA, Hong DS, Birnbaum AE, Taylor MH, Patel SA, et al. innovaTV 207: New combination dosing cohorts in the open label phase 2 study of tisotumab vedotin in solid tumors. 2022;40:TPS6100–TPS6100.

Lassman AB, Van Den Bent MJ, Gan HK, Reardon DA, Kumthekar P, Butowski N, et al. Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial. Neuro Oncol. 2019;21:106–14.

Article  CAS  PubMed  Google Scholar 

O’Malley DM, Oaknin A, Matulonis UA, Mantia-Smaldone G, Lim PC, Castro CM, et al. Abstract 5504: Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-agnostic ovarian cancer: final analysis. 2021;19:8–10.

Risbridger GP, Davis ID, Birrell SN, Tilley WD. Breast and prostate cancer: more similar than different. Nat Rev Cancer. 2010;10:205–12.

Article  CAS  PubMed  Google Scholar 

Mamounas EP, Untch M, Mano MS, Huang CS, Geyer CE, von Minckwitz G, et al. Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE. Ann Oncol. 2021;32:1005–14.

Article  CAS  PubMed  Google Scholar 

Hurvitz SA, Wang LS, Chan D, Phan V, Lomis T, McAndrew NP, et al. TRIO-US B-12 TALENT: Phase II neoadjuvant trial evaluating trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early-stage breast cancer. 2022;40:TPS623–TPS623.

Mattes MJ. Radionuclide-antibody conjugates for single-cell cytotoxicity. Cancer. John Wiley and Sons Inc.; 2002. p. 1215–23.

Salvestrini V, Kim K, Caini S, Alkner S, Ekholm M, Skyttä T, et al. Safety profile of trastuzumab-emtansine (T-DM1) with concurrent radiation therapy: a systematic review and meta-analysis. Radiother Oncol. 2023;186: 109805.

Article  CAS  PubMed  Google Scholar 

Krop IE, Suter TM, Dang CT, Dirix L, Romieu G, Zamagni C, et al. Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer. J Clin Oncol. 2015;33:1136–42.

Article  CAS  PubMed  PubMed Central  Google Scholar 

von Minckwitz G, Huang C-S, Mano MS, Loibl S, Mamounas EP, Untch M, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380:617–28. https://doi.org/10.1056/NEJMoa1814017.

Article  Google Scholar 

Carlson JA, Nooruddin Z, Rusthoven C, Elias A, Borges VF, Diamond JR, et al. Trastuzumab emtansine and stereotactic radiosurgery: an unexpected increase in clinically significant brain edema. Neuro Oncol. 2014;16:1006–9. https://doi.org/10.1093/neuonc/not329.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lassman AB, Pugh SL, Wang TJC, Aldape K, Gan HK, Preusser M, et al. Depatuxizumab-mafodotin in EGFR-amplified newly diagnosed glioblastoma: a phase III randomized clinical trial. Neuro Oncol. 2022;

Narita Y, Muragaki Y, Kagawa N, Asai K, Nagane M, Matsuda M, et al. Safety and efficacy of depatuxizumab mafodotin in Japanese patients with malignant glioma: a nonrandomized, phase 1/2 trial. Cancer Sci. 2021;112:5020–33.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Géraud A, Xu HP, Beuzeboc P, Kirova YM. Preliminary results of the concurrent use of radiotherapy for bone metastases and trastuzumab emtansine in patients with HER2-positive metastatic breast cancer. Cancer/Radiothérapie. 2016;20:312–3.

Article  PubMed  Google Scholar 

Jacot W, Pons E, Frenel JS, Guiu S, Levy C, Heudel PE, et al. Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases. Breast Cancer Res Treat. 2016;157:307–18. https://doi.org/10.1007/s10549-016-3828-6.

Article  CAS  PubMed  Google Scholar 

Geraud A, Xu HP, Beuzeboc P, Kirova YM. Preliminary experience of the concurrent use of radiosurgery and T-DM1 for brain metastases in HER2-positive metastatic breast cancer. J Neurooncol. 2017;131:69–72. https://doi.org/10.1007/s11060-016-2265-z.

Article  CAS  PubMed  Google Scholar 

Zolcsák Z, Loirat D, Fourquet A, Kirova YM. Adjuvant trastuzumab emtansine (T-DM1) and concurrent radiotherapy for residual invasive HER2-positive breast cancer: single-center preliminary results. Am J Clin Oncol Cancer Clin Trials. 2020;43:895–901.

Google Scholar 

Mills MN, Walker C, Thawani C, Naz A, Figura NB, Kushchayev S, et al. Trastuzumab emtansine (T-DM1) and stereotactic radiation in the management of HER2+ breast cancer brain metastases. BMC Cancer. 2021;21:1–8. https://doi.org/10.1186/s12885-021-07971-w.

Article  CAS  Google Scholar 

Bennardo L, Passante M, Cameli N, Cristaudo A, Patruno C, Nisticò SP, et al. Skin manifestations after ionizing radiation exposure: a systematic review. Bioengineering 2021;8:153.

Hariri G, Zhang Y, Fu A, Han Z, Brechbiel M, Tantawy MN, et al. Radiation-guided P-selectin antibody targeted to lung cancer. Ann Biomed Eng. 2008;36:821–30. https://doi.org/10.1007/s10439-008-9444-9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shamay Y, Elkabets M, Li H, Shah J, Brook S, Wang F, et al. P-selectin is a nanotherapeutic delivery target in the tumor microenvironment. Sci Transl Med. 2016. https://doi.org/10.1126/scitranslmed.aaf7374.

Article  PubMed  PubMed Central  Google Scholar 

Dong D, Ni M, Li J, Xiong S, Ye W, Virrey JJ, et al. Critical role of the stress chaperone GRP78/BiP in tumor proliferation, survival, and tumor angiogenesis in transgene-induced mammary tumor development. Cancer Res. 2008;68:498–505.